Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

Breakthrough discovery in cancer research! Scientists uncover a simple genetic strategy to combat aggressive cancers. Learn ...

Previously, Zhang's team had adapted bacterial CRISPR systems into gene-editing ... Sequences within each gene's repetitive region—its TIGR arrays—encode an RNA guide that interacts with ...

Illumina & NashBio announce Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery: San Diego Friday, March 21, 2025, 10:00 Hrs [IST] Illumina ...

BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

However, the array of different damages potentially induced ... these cells dealt with single-strand nicks to their DNA." Using CRISPR technology, Cantor and Dr. Whalen, a postdoctoral researcher ...

Illumina, Inc., a global leader in next-generation sequencing and array-based technologies ... this leading workflow alongside state-of-the-art techniques like Perturb-seq, CRISPR screens, and other ...

However, the array of different damages potentially induced by these ... tools to see how these cells dealt with single-strand nicks to their DNA.” Using CRISPR technology, Cantor and Dr. Whalen, a ...

Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt ...

Doudna, who won a Nobel Prize in Chemistry for her pioneering work on CRISPR gene editing ... mandating the NIH to continue holding off on massive funding cuts for an array of scientific and medical ...